- Conditions
- Malignant Female Reproductive System Neoplasm
- Interventions
- Hydromorphone, Methadone, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Female only
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 1,401
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2, Food Insecurity, Diabetes Mellitus, Type 1
- Interventions
- Nutrition program
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Paclitaxel, Carboplatin, Pembrolizumab, Doxorubicin, Cyclophosphamide, Personalized cancer vaccine (PCV), AB248, pVAC tools neoantigen prediction algorithm, poly-ICLC
- Drug · Biological · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- COVID-19, Vaccine Uptake
- Interventions
- Tough Talks COVID
- Behavioral
- Lead sponsor
- Florida State University
- Other
- Eligibility
- 18 Years to 29 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Tallahassee, Florida
- Conditions
- SARS-CoV Infection
- Interventions
- Losartan
- Drug
- Lead sponsor
- Sharp HealthCare
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 3
- States / cities
- La Mesa, California • San Diego, California
- Conditions
- Transplantation, Kidney
- Interventions
- Tacrolimus (TAC), VEL-101
- Drug
- Lead sponsor
- Veloxis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Gastroschisis
- Interventions
- SoC Staged Silo Closure, Peritoneal Dialysis Solution/Dextrose 1.5%
- Procedure · Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 0 Hours to 12 Hours
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Sickle Cell Disease
- Interventions
- Oxbryta® (voxelotor) 500mg Tablets
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 43
- States / cities
- Mobile, Alabama • Phoenix, Arizona • La Jolla, California + 24 more
- Conditions
- Knee Osteoarthritis, Knee Arthritis, Knee Pain Chronic, Knee Disease, Joint Pain, Osteo Arthritis Knee, Osteoarthritis, Knee
- Interventions
- ROMTech PortableConnect, Traditional Rehabilitation and CPM Device
- Device
- Lead sponsor
- ROM Technologies, INC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 5
- States / cities
- Gilbert, Arizona • Aventura, Florida • Clearwater, Florida + 2 more
- Conditions
- Colorectal Surgery, Quality Improvement, Perioperative Care, ERAS
- Interventions
- ERAS perioperative care, Standard perioperative care, Noninvasive hemodynamic monitoring
- Procedure
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 664 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Colorectal Cancer
- Interventions
- ONO-4578, Opdivo®, Oxaliplatin, 5-Fluorouracil, Bevacizumab, Leucovorin
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Los Angeles, California • Lone Tree, Colorado + 8 more
- Conditions
- Venous Leg Ulcer (VLU), Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
- Interventions
- Tri-Membrane Wrap™, Membrane Wrap™, Membrane Wrap-Hydro™, Standard of Care
- Device · Other
- Lead sponsor
- BioLab Holdings
- Industry
- Eligibility
- Not listed
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Toms River, New Jersey • Houston, Texas
- Conditions
- Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery
- Interventions
- Cold and Compression, SOC (Standard of care)
- Device · Other
- Lead sponsor
- Ochsner Health System
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Bacterial Pneumonia
- Interventions
- Cefiderocol, Standard of Care Antibiotic
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Hartford, Connecticut • Jacksonville, Florida + 4 more
- Conditions
- Leukemia, Myeloid Leukemia, Monocytic Leukemia
- Interventions
- Venetoclax, Azacitidine, Mitoxantrone
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Diabetic Foot Ulcer, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM), Neuroischemic Foot Ulcer, Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer), Chronic Wound Care
- Interventions
- Platelet Rich Plasma
- Device
- Lead sponsor
- Estar Medical dba Medical Technologies, LTD
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Corpus Christi, Texas
- Conditions
- Small Bowel Crohn's Disease
- Interventions
- Not listed
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Ulcers
- Interventions
- NIRS imaging in addition to SOC
- Device
- Lead sponsor
- Kent Imaging Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- New Braunfels, Texas • San Antonio, Texas • San Marcos, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Cevostamab, Pomalidomide, Dexamethasone, Daratumumab, Elotuzumab, Carfilzomib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 10
- States / cities
- Duarte, California • Irvine, California • New Haven, Connecticut + 7 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Benlysta, Standard of Care (SoC) Therapy
- Biological · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2025
- U.S. locations
- 102
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Goodyear, Arizona + 85 more
- Conditions
- Non Small Cell Lung Carcinoma NSCLC
- Interventions
- Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 953 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 15
- States / cities
- Anaheim, California • San Diego, California • Santa Rosa, California + 12 more
- Conditions
- Wounds and Injuries
- Interventions
- AR/101, Placebo
- Drug
- Lead sponsor
- Arava Bio Tech Ltd.
- Industry
- Eligibility
- 25 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Extensive Stage-small Cell Lung Cancer
- Interventions
- Ifinatamab deruxtecan, Atezolizumab, Carboplatin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
- Conditions
- Transthyretin Amyloid Cardiomyopathy (ATTR CM)
- Interventions
- NNC6019-0001, Placebo (NNC6019-0001)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 63
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 49 more